{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-006912","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2024-05-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.871048+00:00","generated_at":"2026-06-01T08:51:58.286677+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Dermata Therapeutics regains Nasdaq compliance with publicly held shares rule","bullets":["Received Nasdaq deficiency notice on May 20, 2024 for failing Rule 5550(a)(4) requiring at least 500,000 publicly held shares.","Provided additional information and as of May 24, 2024, the Company has regained compliance and the matter is closed.","No further action required; common stock (DRMA) and warrants (DRMAW) remain listed on Nasdaq."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-006912","json":"https://secwatch.observer/filing/0001654954-24-006912.json","markdown":"https://secwatch.observer/filing/0001654954-24-006912.md","text":"https://secwatch.observer/filing/0001654954-24-006912.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424006912/0001654954-24-006912-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424006912/drma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T08:51:58.286677+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}